Abstract
Joubert syndrome (JBTS) and Meckel–Gruber syndrome (MKS) are rare recessive disorders caused by defects of cilia, and they share overlapping clinical features and allelic loci. Mutations of MKS1 contribute approximately 7% to all MKS cases and are found in some JBTS patients. Here, we describe a JBTS patient with two novel mutations of MKS1. Whole exome sequencing (WES) revealed c.191-1G > A and c.1058delG compound heterozygous variants. The patient presented with typical cerebellar vermis hypoplasia, hypotonia, and developmental delay, but without other renal/hepatic involvement or polydactyly. Functional studies showed that the c.1058delG mutation disrupts the B9 domain of MKS1, attenuates the interactions with B9D2, and impairs its ciliary localization at the transition zone (TZ), indicating that the B9 domain of MKS1 is essential for the integrity of the B9 protein complex and localization of MKS1 at the TZ. This work expands the mutation spectrum of MKS1 and elucidates the clinical heterogeneity of MKS1-related ciliopathies.
Introduction
Caused by defects of cilia, a variety of disorders are named ciliopathies (; ; ). Joubert syndrome (JBTS) and Meckel–Gruber syndrome (MKS) are two kinds of typical ciliopathies sharing overlapping clinical phenotypes, such as central nervous system malformation, renal/liver disease, and polydactyly (; ; ). JBTS is characterized by cerebellar vermis hypoplasia, which shows a typical molar tooth sign (MTS) on magnetic resonance imaging (MRI) (; ). Additional clinical symptoms may also be associated with brain malformations, including cystic kidney disease, liver fibrosis, polydactyly, or retinal dystrophy (). Most JBTS patients are expected to have normal life spans (). MKS is a rare lethal ciliopathy characterized by occipital encephalocele, cystic renal dysplasia, and postaxial polydactyly (). Ciliary defects in MKS result in perinatal lethality.
Genetic analysis has revealed that JBTS and MKS share more than 10 allelic loci (; ; ; ; ), most of which encode proteins concentrated to the ciliary transition zone (TZ), a specialized region at the ciliary base controlling the composition of cilia (; ; ). MKS1 is a TZ protein found in MKS, JBTS, and Bardet–Biedl syndrome (BBS), which is a ciliopathy characterized by obesity, retinitis pigmentosa, polydactyly, intellectual disability, and renal abnormalities (; ; ). Mutations of the MKS1 gene contribute to approximately 7% of all reported MKS cases (), but only a few mutations in MKS1 have been reported to cause JBTS (; ; ; ; ). In the present study, we identified a patient with two novel MKS1 mutations in a JBTS cohort. In contrast to most reported JBTS cases with ≥ 1 non-truncating mutation of MKS1, this patient carried two mutations leading to truncated forms of MKS1. Further studies showed that the truncated protein failed to interact with B9D2 and attenuated the TZ localization. These findings extend the spectrum of MKS1 mutations in ciliopathies.
Materials and Methods
Whole Exome Sequencing and Variants Analysis
The exomes were captured by using the Agilent SureSelect Human All Exon V6 Kit (Agilent Technologies Inc.) and sequencing on an Illumina NovaSeq 6000 platform (Illumina Inc., CA, United States). Burrows−Wheeler Aligner and SAMtools were used to align the NGS reads to the hg19 reference genome (GRCh37). PCR duplicates were removed by Picard tools. Variants and small InDels were called by Genome Analysis Toolkit (GATK), annotated with Ensembl Variant Effect Predictor () and filtered as described previously (). Finally, all the variants were annotated according to American College of Medical Genetics and Genomics (ACMG) guidelines (), and the variants from known causative genes of JBTS were analyzed with priority. Sanger sequencing was performed for variant validation.
RNA Extraction and PCR
TempusTM Blood RNA Tube (Thermo Fisher Scientific, MA, United States) and TempusTM Spin RNA Isolation Kit (Thermo Fisher Scientific, MA, United States) were used for blood collection and RNA extraction, respectively. SuperScript IV First-Strand Synthesis System Kit (Thermo Fisher Scientific, MA, United States) was used for reverse transcription. The forward primer (5′-CCGAGTCCACCTGCAAAGAA-3′) used for cDNA amplification crossed the junction of exon 1 and exon 2, while the reverse primer (5′-TTCTCCCCCTCCGTCTCAAT-3′) was located at the beginning of exon 8. For qPCR, the primers of MKS1 5′-AAGGTGGCTCACTTCTCCTACC-3′ and 5′-AGAGGACCTCACAGTAGAGCAC-3′ and the primers of GAPDH 5′-GTCTCCTCTGACTTCAACAGCG-3′ and 5′-ACCACCCTGTTGCTGTAGCCAA-3′ were used.
Plasmid Constructs
The cDNAs of MKS1 and B9D2 were amplified by PCR from a cDNA library prepared from HEK293 cells. MKS1 variants were cloned into the pLV-FLAG lentiviral vector. B9D2 was inserted into pCMV-HA. All plasmid sequences were validated by Sanger sequencing.
Cell Culture, Plasmid Transfection, Lentivirus Package, and Infection
HEK293T cells were grown in Dulbecco’s modified Eagle medium (DMEM, Sigma, MO, United States) supplemented with 10% FBS (Sigma, MO, United States), 100 U/ml penicillin, and 0.1 mg/ml streptomycin. RPE1 cells were grown in DMEM/F12 (1:1 mixture) (Sigma, MO, United States) supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Transfections of HEK293T cells were performed using linearized polyethyleneimine (PEI) (Polysciences Inc., PA, United States). pLV-FLAG plasmids harboring MKS1 variants were transfected into HEK293 cells with psPAX2 and pMD2.g by the PEI method. Media containing virus were filtered through a 0.45 μm membrane filter and added into plates with RPE1 cells in the presence of 6 μg/ml polybrene (Santa Cruz, TX, United States). After 48 h of infection, RPE1 cells were selected with 10 μg/ml puromycin for 2 weeks.
Co-immunoprecipitation and Western Blot Analysis
For co-immunoprecipitation (co-IP), transfected HEK293T cells were rinsed with ice-cold PBS and scraped into IP lysis buffer (20 mM Tris–HCl, pH = 7.5; 150 mM NaCl; 0.5 mM EDTA; and 0.5% Triton X-100) supplemented with protease inhibitor cocktail. After 20 min, cell lysates were cleared by 10,000 × g centrifugation at 4°C for 10 min. The supernatant was used for the co-IP assay by shaking with FLAG M2 beads (Sigma-Aldrich, MO, United States) for 2 h at 4°C. After three washes, proteins binding to FLAG beads were eluted with IP buffer containing 200 μg/ml 3 × FLAG peptides (Sigma-Aldrich, MO, United States).
For Western blot analysis, whole cell lysates or the elution products from the co-IP were denatured with 2 × SDS sample buffer, resolved on SDS-polyacrylamide gel electrophoresis, and subjected to Western blotting. The following antibodies were used for Western blot analysis: anti-FLAG (1:5,000, Sigma-Aldrich, MO, United States), anti-HA (1:3,000, Sigma-Aldrich, MO, United States), goat anti-mouse IRDye 680RD (1:15,000; LI-COR, NE, United States), and goat anti-rabbit IRDye 800CW (1:20,000; LI-COR, NE, United States).
Immunostaining and Confocal Imaging
For immunostaining, RPE1 cells were seeded on coverslips in six-well plates. After serum starvation for 48 h, cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min, and the fixed cells were permeabilized by −20°C cold methanol or 0.3% Triton X-100 for 10 min. After washing twice with PBS, cells were stained using primary antibodies in blocking buffer (PBS containing 1% bovine serum albumin and 0.1% Triton X-100) for 1 h at room temperature. After washing with PBS twice, cells were incubated with secondary antibodies in blocking buffer for 1 h at room temperature. DNA was visualized by DAPI (Sigma-Aldrich, MO, United States). Samples were visualized using a FV3000 confocal microscope (Olympus, Tokyo, Japan) with a 40 × /NA1.4 objective (Olympus, Tokyo, Japan). Data from three independent experiments was used for intensity quantification.
Results
Novel Mutations of MKS1 Are Associated With Joubert Syndrome
Whole exome sequencing (WES) of 151 patients in a JBTS cohort resulted in the identification of two likely pathogenic MKS1 variants. The proband, II:2, is the second child of non-consanguineous parents without related medical history (Figure 1A). She was born full-term by normal delivery, weighing 4,050 g and measuring 55 cm in height. The proband was hospitalized at the age of 5 months, and she was diagnosed with hypotonia and developmental delay. Brain MRI showed typical molar tooth sign, indicating severe cerebellar vermis hypoplasia (Figure 1B). No renal/hepatic involvement, polydactyly, or agenesis of the corpus callosum was observed (Table 1). Several rare deleterious variants in the known JBTS genes were found by WES (Supplementary Table 1). WES found the compound heterozygous variants in the MKS1 gene (GenBank: NM_017777.3), but other variants are heterozygous (Supplementary Table 1). The paternally inherited variant of MKS1 is mutated at the canonical splice acceptor site, and it is also known as rs201362733 with a rare frequency (0.00001202) in gnomAD (Figures 1C,D). The maternally inherited variant, c.1058delG, is a deletion of one nucleotide causing a frameshift and premature stop, p.G353Efs∗2 (Figures 1C,D). Thus, both of the two variants of MKS1 were classified as “pathogenic,” according to the ACMG guidelines (). The absence of these two variants in her sister revealed that she is not a carrier.
FIGURE 1
TABLE 1
| Sample name | 129C |
| Gender | Female |
| Age | 5 months |
| Ethnic | Chinese |
| Mutation 1 | c.191-1G > A |
| p.S64Mfs*12 | |
| Mutation 2 | c.1058delG |
| p.G353Efs*2 | |
| Molar tooth sign | + |
| Developmental delay | + |
| Respiratory abnormality | – |
| Hypotonia | + |
| Oculomotor apraxia | – |
| Retinal involvement | NA |
| Renal involvement | – |
| Liver involvement | – |
| Limb anomalies | – |
| Agenesis of the corpus callosum | – |
Clinical features and genotype.
Confirmation for an Abnormal Transcript of MKS1
The mutational effect of c.191-1G > A was validated by reverse transcription PCR. Surprisingly, only one band was observed in the proband, her father, her mother, her sister, and a healthy control (Figure 2A). Sanger sequencing showed one nucleotide deletion at the beginning of exon 3 rather than skipping exon 3, which was caused by the failure of correct splicing in c.191-1G > A mutated samples (the proband and father) (Figures 2B,C). This deletion resulted in a frameshift and a premature stop, which is annotated as p.S64Mfs∗12. The mRNA level was comparable to the sibling and healthy control (Figure 2D).
FIGURE 2
The B9 Domain of MKS1 Is Required for the Transition Zone Localization and Interaction With B9D2
B9-containing proteins are highly conserved proteins present only in organisms assembling cilia (). MKS1 encodes a protein with 559 amino acids and the B9 domain localizes at the C-terminus. The c.191-1G > A variant was predicted to generate a short peptide containing 64 correct amino acids, suggesting complete loss of function. The c.1058delG variant caused early termination of the translation of MKS1, which caused the partial loss of the B9 domain (314–493) and loss of the C-terminal tail (494–559). To confirm the pathogenicity, we established RPE1 cell lines stably expressing FLAG-tagged wild-type, MKS1 1-353 (to mimic p.G353Efs∗2), or B9 domain lacking MKS1 (Figure 3A). Immunoblots confirmed the expression of the variants (Figure 3B). Previous studies have shown that MKS1 mainly localizes at the ciliary transition zone (; ; ; ). Therefore, we determined whether the MKS1 1-353 disrupted the localization of MKS1 by immunostaining. Almost all cells expressing wild-type MKS1 had FLAG signal at the transition zone, but the localization of MKS1 1-353 or the B9 domain-lacking mutant was largely attenuated (Figures 3C,D). It has been shown that the three B9 proteins, MKS1, B9D1, and B9D2, form a protein complex, the integrity of which is essential for their function (; ; ; ). In this complex, MKS1 predominantly interacts with B9D2 (). To test whether the mutation affects B9 protein complex formation, we performed co-immunoprecipitation assays. Immunoblots showed that wild-type MKS1 but not the MKS1 1-353 or B9 domain-lacking MKS1 interacted with B9D2 (Figure 3E). These results demonstrate that the B9 domain is essential for the localization and activity of MKS1 protein.
FIGURE 3
Discussion
In this study, we report a JBTS patient with two novel MKS1 mutations displaying global developmental delay, MTS, and hypotonia. Additional brain anomalies such as agenesis of the corpus callosum, which is more frequent in MKS than JBTS (), were not observed. This patient belongs to JBTS, because no renal or liver involvement and no limb anomalies were displayed.
A hypothesis has been proposed for the genotype–phenotype correlation as follows: two null alleles of MKS1 result in MKS; one null allele and one hypomorphic allele result in JBTS; and two hypomorphic alleles result in BBS (). In this study, the proband has two truncating mutations but has JBTS. This situation has also occurred in three other cases as follows: homozygous splice acceptor site mutation of c.1461-2A > G in COR340 (), homozygous frameshift mutation of c.1528dupC (p.R510Pfs∗81) in UW31-3, and homozygous splice acceptor site mutation of c.1589-2A > T in UW150-3 (; ). Taken together, these findings suggested that the genotype–phenotype correlation is more complicated in MKS1-mutated ciliopathies.
Previous landmark studies have shown that the integrity of the B9 complex may be essential for the control of the entry and exit of ciliary components (; ). We found that loss of the B9 domain of MKS1 largely attenuates its transition zone localization and disrupts the interaction with B9D2. These findings are consistent with previous studies. Three major protein modules locate at the TZ region, namely the NPHP complex, the B9 complex, and the TMEM–TCTN complex. The disruption of the B9 complex possibly changes the structure of the three key modules and results in ciliopathies.
In summary, we identified two novel null mutants of MKS1 resulting in JBTS, expanding the genetic basis of JBTS. Our findings further implicate that clinical features of MKS1 mutations are more complicated than the previously proposed genotype–phenotype correlation model of the MKS1 gene. Finally, these findings will be helpful for the genetic testing of JBTS patients and their families.
Statements
Data availability statement
The data in this study are available from MC, upon reasonable request.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of the National Research Institute for Family Planning of China. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.
Author contributions
MC, XM, JZ, and ML conceived and directed the project. GZ collected the blood sample and medical information of the patients. YS analyzed and interpreted the medical data. ML, YS, and CL prepared the samples and performed the WES. ZC and ML analyzed and interpreted the WES data. RH, ZL, and DM performed the biochemical analysis and imaging. MC, XM, JZ, and ML wrote the manuscript with the help of all the other authors. All authors contributed to the article and approved the submitted version.
Funding
The work was supported by the National Key Research and Development Program of China (2016YFC1000307) to XM, the National Natural Science Foundation of China (91954123, 31972887) to MC, Clinical Research Projects of Shanghai Municipal Health Commission (20194Y0133) to MC, the Non-Profit Central Research Institute Fund of the National Research Institute for Family Planning (2020GJZ05) to ML, the National Natural Science Foundation of China (31701172) to DM, and the Natural Science Foundation of Tianjin (18JCQNJC09900) to DM.
Acknowledgments
We are very grateful to the patients and their parents for their participation in this study and their permission regarding this publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.576235/full#supplementary-material
References
1
BaalaL.RomanoS.KhaddourR.SaunierS.SmithU. M.AudollentS.et al (2007). The meckel-gruber syndrome gene, MKS3, is mutated in Joubert syndrome.Am. J. Hum. Genet.80186–194. 10.1086/510499
2
Bachmann-GagescuR.DempseyJ. C.BulgheroniS.ChenM. L.D’ArrigoS.GlassI. A.et al (2020). Healthcare recommendations for Joubert syndrome.Am. J. Med. Genet. A182229–249. 10.1002/ajmg.a.61399
3
Bachmann-GagescuR.DempseyJ. C.PhelpsI. G.O’RoakB. J.KnutzenD. M.RueT. C.et al (2015). Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity.J. Med. Genet.52514–522. 10.1136/jmedgenet-2015-103087
4
BaderI.DeckerE.MayrJ. A.LunzerV.KochJ.BoltshauserE.et al (2016). MKS1 mutations cause Joubert syndrome with agenesis of the corpus callosum.Eur. J. Med. Genet.59386–391. 10.1016/j.ejmg.2016.06.007
5
BarkerA. R.RenzagliaK. S.FryK.DaweH. R. (2014). Bioinformatic analysis of ciliary transition zone proteins reveals insights into the evolution of ciliopathy networks.BMC Genomics15:531. 10.1186/1471-2164-15-531
6
BrancatiF.DallapiccolaB.ValenteE. M. (2010). Joubert Syndrome and related disorders.Orphanet. J. Rare Dis.5:20. 10.1186/1750-1172-5-20
7
ChihB.LiuP.ChinnY.ChalouniC.KomuvesL. G.HassP. E.et al (2011). A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain.Nat. Cell Biol.1461–72. 10.1038/ncb2410
8
DaweH. R.SmithU. M.CullinaneA. R.GerrelliD.CoxP.BadanoJ. L.et al (2007). The meckel-gruber syndrome proteins MKS1 and meckelin interact and are required for primary cilium formation.Hum. Mol. Genet.16173–186. 10.1093/hmg/ddl459
9
DempseyJ. C.PhelpsI. G.Bachmann-GagescuR.GlassI. A.TullyH. M.DohertyD. (2017). Mortality in Joubert syndrome.Am. J. Med. Genet. A.1731237–1242. 10.1002/ajmg.a.38158
10
DowdleW. E.RobinsonJ. F.KneistA.Sirerol-PiquerM. S.FrintsS. G.CorbitK. C.et al (2011). Disruption of a ciliary B9 protein complex causes Meckel syndrome.Am. J. Hum. Genet.8994–110. 10.1016/j.ajhg.2011.06.003
11
Garcia-GonzaloF. R.CorbitK. C.Sirerol-PiquerM. S.RamaswamiG.OttoE. A.NoriegaT. R.et al (2011). A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition.Nat. Genet.43776–784. 10.1038/ng.891
12
HartillV.SzymanskaK.SharifS. M.WhewayG.JohnsonC. A. (2017). Meckel-gruber syndrome: an update on diagnosis, clinical management, and research advances.Front. Pediatr.5:244. 10.3389/fped.2017.00244
13
HildebrandtF.BenzingT.KatsanisN. (2011). Ciliopathies.N. Engl. J. Med.3641533–1543. 10.1056/NEJMra1010172
14
IrfanullahK. S.UllahI.NasirA.MeijerC. A.Laurense-BikM.DunnenJ. T. D.et al (2016). Hypomorphic MKS1 mutation in a Pakistani family with mild Joubert syndrome and atypical features: expanding the phenotypic spectrum of MKS1-related ciliopathies.Am. J. Med. Genet. A1703289–3293. 10.1002/ajmg.a.37934
15
JoubertM.EisenringJ. J.RobbJ. P.AndermannF. (1969). Familial agenesis of the cerebellar vermis. A syndrome of episodic hyperpnea, abnormal eye movements, ataxia, and retardation.Neurology19813–825. 10.1212/wnl.19.9.813
16
KyttalaM.TallilaJ.SalonenR.KopraO.KohlschmidtN.Paavola-SakkiP.et al (2006). MKS1, encoding a component of the flagellar apparatus basal body proteome, is mutated in Meckel syndrome.Nat. Genet.38155–157. 10.1038/ng1714
17
LuoM.CaoL.CaoZ.MaS.ShenY.YangD.et al (2019). Whole exome sequencing reveals novel CEP104 mutations in a Chinese patient with Joubert syndrome.Mol. Genet. Genomic Med.7:e1004. 10.1002/mgg3.1004
18
McLarenW.GilL.HuntS. E.RiatH. S.RitchieG. R.ThormannA.et al (2016). The ensembl variant effect predictor.Genome Biol.17:122. 10.1186/s13059-016-0974-4
19
NovarinoG.AkizuN.GleesonJ. G. (2011). Modeling human disease in humans: the ciliopathies.Cell14770–79. 10.1016/j.cell.2011.09.014
20
ReiterJ. F.LerouxM. R. (2017). Genes and molecular pathways underpinning ciliopathies.Nat. Rev. Mol. Cell Biol.18533–547. 10.1038/nrm.2017.60
21
RichardsS.AzizN.BaleS.BickD.DasS.Gastier-FosterJ.et al (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.Genet. Med.17405–424. 10.1038/gim.2015.30
22
RomaniM.MicalizziA.KraouaI.DottiM. T.CavallinM.SztrihaL.et al (2014). Mutations in B9D1 and MKS1 cause mild Joubert syndrome: expanding the genetic overlap with the lethal ciliopathy Meckel syndrome.Orphanet. J. Rare Dis.9:72. 10.1186/1750-1172-9-72
23
SangL.MillerJ. J.CorbitK. C.GilesR. H.BrauerM. J.OttoE. A.et al (2011). Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.Cell145513–528. 10.1016/j.cell.2011.04.019
24
SattarS.GleesonJ. G. (2011). The ciliopathies in neuronal development: a clinical approach to investigation of Joubert syndrome and Joubert syndrome-related disorders.Dev. Med. Child Neurol.53793–798. 10.1111/j.1469-8749.2011.04021.x
25
SlaatsG. G.IsabellaC. R.KroesH. Y.DempseyJ. C.GremmelsH.MonroeG. R.et al (2016). MKS1 regulates ciliary INPP5E levels in Joubert syndrome.J. Med. Genet.5362–72. 10.1136/jmedgenet-2015-103250
26
ValenteE. M.LoganC. V.Mougou-ZerelliS.LeeJ. H.SilhavyJ. L.BrancatiF.et al (2010). Mutations in TMEM216 perturb ciliogenesis and cause Joubert. Meckel and related syndromes.Nat. Genet.42619–625. 10.1038/ng.594
27
VilbouxT.DohertyD. A.GlassI. A.ParisiM. A.PhelpsI. G.CullinaneA. R.et al (2017). Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center.Genet. Med.19875–882. 10.1038/gim.2016.204
Summary
Keywords
cilia, ciliopathy, Joubert syndrome, B9 proteins, MKS1
Citation
Luo M, He R, Lin Z, Shen Y, Zhang G, Cao Z, Lu C, Meng D, Zhang J, Ma X and Cao M (2020) Novel Compound Heterozygous Variants in MKS1 Leading to Joubert Syndrome. Front. Genet. 11:576235. doi: 10.3389/fgene.2020.576235
Received
25 June 2020
Accepted
14 September 2020
Published
14 October 2020
Volume
11 - 2020
Edited by
Fasil Tekola-Ayele, National Institutes of Health (NIH), United States
Reviewed by
Sheng Wang, University of California, San Francisco, United States; Jeffrey Dennis Calhoun, Northwestern University, United States; Ruxandra Bachmann-Gagescu, University of Zurich, Switzerland
Updates
Copyright
© 2020 Luo, He, Lin, Shen, Zhang, Cao, Lu, Meng, Zhang, Ma and Cao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing Zhang, Jingzhang@shsmu.edu.cnXu Ma, maxu_nhgrc@163.comMuqing Cao, muqingcao@sjtu.edu.cn
†These authors have contributed equally to this work
This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.